The Latest Breaking News from Merck

The Dow Jones fell Thursday after initial jobless claims. Meta stock soared 20% on a $40 billion stock buyback.

Merck & Co.’s COVID-19 pill is giving rise to new mutations of the virus in some patients, according to a study that underscores the risk of trying to intentionally alter the pathogen’s genetic code.

Tech names Nvidia remain absent as medical, oil, retail and machinery stocks top the list of new buys by the best mutual funds in bear market.

United Therapeutics is the IBD Stock Of The Day as competition heats up in its lung disease market. UTHR stock is eyeing two potential buy points.

Merck is navigating a looming patent expiration for its blockbuster Keytruda. Now, Merck stock is trading at its highest point in decades.

BEIJING: Desperate families searching for critical Covid-19 medication in China, faced with bare pharmacy shelves and an explosion of cases, are being driven into murky online marketplaces rife with price gouging and fraud.

The long-awaited cancer vaccine revolution is getting a little closer to reality. New data from Moderna Inc. and Merck & Co. suggest that after decades of failures, researchers are finally figuring out the right way to design a vaccine that can teach immune cells how to recognize and combat tumors.

The healthcare industry is poised to grow significantly in the coming years. Moreover, as healthcare stocks tend to perform relatively well despite macro uncertainties due to inelastic demand for their products and services, high-flying pharma stocks Novo Nordisk (NVO), AbbVie (ABBV), and Merck & Co (MRK) might be ideal investments…

Gilead and Arcus toppled Tuesday after their lung-cancer regimen trailed a rival concoction from Roche. RCUS stock skidded more than 20%.